Development Center for Biotechnology

Academia Sinica

Chang Gung Memorial Hospital

Chuan-Lung Hsu

Cheng-Chou Yu

Alice L Yu

Yi-Jen Chen

Shih-Hsien Chuang

John Yu

Yi-Chang Chen

Jiann-Shiun Lai

Ying-Yung Lok

Szu-Liang Lai

Win-Yin Wei

Chia-Cheng Wu

Tsung-Han Hsieh

Chao-Pin Lee

Li-Ya Wang

Chien-Tsun Kuan

Shu-Ping Yeh

Chih-Lun Hsiao

Yen-Yu Wu

Yi-San Tsai

Yi-Jiue Tsai

Juo-Yu Huang

Yu-Chin Nieh

Ya-Hui Wang

Mei-Chi Chan

Li-Shuang Ai

Ling-Yueh Hu

Yan-Da Lai

Shih-Rang Yang

An anti-PD-L1 antibody, or an antigen-binding fragment thereof, comprising: a heavy chain variable region comprising the three CDRs with the sequences of SEQ ID NOs: 2-4, 6-8, 10-12, 14-16, or 18-20; and/or a light chain variable region comprising the three CDRs with the sequences of SEQ ID NOs: 22-24, 26-28, 30-32, 34-36, or 38-40, wherein the antibody is a chimeric, humanized, composite, or human antibody.

Anti-human PD-L1 antibodies and their uses

An immunoconjugate includes an anti-Globo H antibody, or a binding fragment thereof, and a therapeutic agent or a label, having the formula: Ab&#x2212;(L&#x2212;D), wherein Ab is the anti-Globo H antibody or the binding fragment thereof, L is a linker or a direct bond, D is the therapeutic agent or the label, and m is an integer from 1 to 8. The antibody may be a monoclonal antibody, which may be a humanized antibody. A method for treating a cancer includes administering to a subject in need of such treatment a pharmaceutically effective amount of an immunoconjugate containing an antibody against Globo H, or a binding fragment thereof, and a therapeutic agent covalently conjugated with the antibody.

Antibody-drug conjugates containing anti-Globo H antibodies and uses thereof

The present invention relates to an antibody or antigen-binding fragment thereof that bind human vascular endothelial growth factor receptor 2 (VEGFR-2). The present invention also relates to a method for inhibiting VEGFR-2-mediated signaling in a subject in need, a method for treating diseases and/or disorders caused by or related to VEGFR-2 activity and/or signaling in a subject afflicted with the diseases and disorders, a method for treating tumor in a subject afflicted with the tumor, a method for inhibiting cell proliferation of endothelial cells in a subject in need, and a method for detecting human vascular endothelial growth factor receptor in a sample.

Anti-VEGFR antibody and uses thereof

A method for treating cancer includes administering to a subject in need thereof an antibody against a transmembrane and coiled-coil domains protein 3 (TMCC3), wherein the antibody binds to an epitope in an extracellular domain of TMCC3. The antibody binds to an epitope in an intercoil domain of TMCC3. A method of diagnosing or assessing a cancer condition includes assessing a level of expression or activity of a transmembrane and coiled-coil domains protein 3 (TMCC3) in a sample, wherein an increase in the level of expression of activity of TMCC3 as compared to a standard indicates the presence of cancer stem cells in the sample.

Methods for suppressing cancer by inhibition of TMCC3

Growing community of inventors

Taipei, Taiwan

Chuan-Lung Hsu